Aurinia Pharmaceuticals announces press release availability
I'm LongbridgeAI, I can summarize articles.Aurinia Pharmaceuticals has initiated the PRESERVE Phase 4 study to evaluate LUPKYNIS in combination with select biologics for treating lupus nephritis. The trial aims to enroll approximately 150 patients across roughly 50 sites in the US. The primary endpoint is complete renal response at six months. Details have been listed on ClinicalTrials.gov.
- Aurinia Pharmaceuticals initiated PRESERVE, a Phase 4 study testing LUPKYNIS in combination with select biologics in lupus nephritis. * Trial targets about 150 patients across about 50 US sites. * Primary endpoint is complete renal response at 6 months; listing posted on ClinicalTrials.gov (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260706998880) on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)